A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)
Clinical trial NCT02927301 · COMPLETED
Trial details
- NCT number
- NCT02927301
- Sponsor
- Genentech, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-04-20
- Primary completion
- 2020-05-07
- Enrollment
- 181
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.